

Together We Discover

Corporate Presentation April 2023

Forward Looking Statements

This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.

Certain statements contained in this presentation, other than present and historical facts and conditions independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include those regarding preliminary financial results for the full year 2022; expectations of future profitability; plans for geographic expansion; the anticipated launch of argenx's subcutaneous ("SC") product in the U.S.; the initiation, timing, progress and results of our anticipated clinical development, data readouts and regulatory milestones and plans; strategic priorities, including the timing and outcome of regulatory filings and regulatory approvals, and anticipated expansion in generalized myasthenia gravis (gMG) and IgG-mediated autoimmune diseases; the potential of argenx's innovative clinical programs; and the nomination of new development candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission ("SEC") filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this presentation. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners.



We are on a **bold mission**

Transforming the lives of patients with severe autoimmune disease through immunology innovation



Redefining Autoimmune Diseases With Precision Medicine Approach

Autoimmunity is Prime for **REVOLUTION**



A pipeline of precision tools

Redefine our pipeline of autoimmune diseases as **IgG-mediated or complement-driven**

Offer **new targeted treatment** modality in diseases where **innovation** is most needed



arg

Redefining What 'Well-Controlled' Means for the Patient

We want to transform gMG treatment for patients

Achieve minimal symptom expression

Reduce reliance on broad immunosuppressants

Minimize treatment burden

Regain control of their lives, including professionally and socially



...and gMG is just the **beginning**


Pioneer with Our Science Lead with Compassion for our Patients

argenx 2025: A Leading, Sustainable Immunology Company

Drive Impact Through Innovation Build the Company We Want to Work For




2022: Transformed into an Integrated Immunology Company



2022: Strengthened Efgartigimod Data Story

SC Noninferiority to IV Clear Clinical Benefit in ITP IgG reduction (%) in all ADAPT-SC and ADAPT participants LS-Mean Platelet Count Change From Baseline $$(x10^{9}\mbox{t})$$ 40 n Mean IgG reduction % 20 -30--60--20 0 12 24 Week - VYVGART - PLACEBO 8 10 Baseline1 2 - 4 -----SC efgartigimod VYVGART Placebo (ADAPT) IV efgartigimod (ADAPT)

Broadened Safety Database




Solidifying FcRn Leadership with Deep Repertoire of Preclinical and Translational Data






2023: Key Drivers of our Path to Profitability



Reach More Patients with VYVGART Globally





IgG Autoantibodies Serve as Unifying Biology Rationale for POC Indications

clinical Pioneer FcRn class of medicines

DSG-1 La/SSB PLA2R DSG-3 **BP230 AChR** MuSK **TSHR**

Contactin1 Ro/SSA Mi-2 THSd7A **MPO-ANCA ANA NF155 GPIIb/IIIa HMGCR** DSA NELL1 **PR3-ANCA GPCR BP180** LRP4 JO-1 SRP Immune complexes








Patient numbers are U.S. prevalence from argenx market research

Steady Cadence of Data Readouts Over Next Several Years



Patient numbers are U.S. prevalence from argenx market research

ARGX-117: Targets C2 at Junction of Classical and Lectin Pathways



Three Indications Selected Based on Biology Rationale

clinical Broaden immunology pipeline

Indication selection starts with autoimmune diseases driven by classical and/or lectin pathway


Phase 2 proof-of-concept trial underway in multifocal motor neuropathy (MMN) with interim data expected in mid-2023


Phase 2 trials to start in delayed graft function and dermatomyositis



ARGX-117: Strong Translational Biology Rationale for C2 Blockade in MMN








A-GM1 antibody mediated complement attack on the Schwann cell membrane

Significant disruption to the axoglial junction and cytoplasmic paranodal loops resulting in conduction block – hall mark of MMN



Significant reduction of injury to paranodal proteins at the Nodes of Ranvier improves respiratory function in vivo



ARGX-119: MuSK Agonist with Broad Potential in clinical Neuromuscular Disease Broaden immunology pipeline MOTOR NEURON First-in-Human Phase 1 Healthy Volunteer Study ••• • • First-in-ACETYLCHOLINE AGRIN Patient RP4 Single Ascending Dose Multiple Ascending Dose Congenital Myasthenic AChR Syndrome (CMS) 10 dose cohorts MuSK MUSCLE 3 dose cohorts/4 weekly doses RAPSYN

First-in-patient trial in CMS to serve as proof of biology

Translational work ongoing in amyotrophic lateral sclerosis (ALS)



Positioned for Long-term Franchise Growth

Neurology

Hematology and Rheumatology

Dermatology

Nephrology

gMG, CIDP, Myositis, TED, MMN, CMS, Musk MG, ALS ITP, Sjogren's, POTS, Anca Vasculitis Pemphigus, Bullous Pemphigoid, Dermatomyositis Membranous Nephropathy, Lupus Nephritis, AMR, DGF

Innovation Ecosystem discovery **Build out** innovation UNIVERSITY OF ecosystem Halozyme OXFORD **MEDIS** Delivering Innovative Healthcare Ч VIB FUJIFILM **GENPHARM** de Duve Institute **Diesynth** [[-]] **IQVIA** AGOMAB hhu Universität Düsseldorf THERAPEUTICS elektrofi abbvie THE UNIVERSITY E patheon of EDINBURGH University of Colorado Anschutz Medical Campus L U by Thermo Fisher Scientific Û Lonza Amsterdam UMC MC Y FairJourney **UTSouthwestern CHUGAI Biologics** Medical Center UNIVERSITÄT ZU LÜBECK Dualyx Authera 🌾 NYU zailab **UMC Utrecht** Sanguin UNIVERSITEIT GENT

Positioned for a Catalyst-Rich 2023

Planned Commercial Milestones

VYVGART gMG Approval in ChinaYE 2023VYVGART gMG Approval in Canada3Q 2023VYVGART gMG Launch in France, UK, ItalyYE 2023SC efgartigimod gMG PDUFA DateJune 20, 2023SC efgartigimod gMG Approval in EU4Q 2023SC efgartigimod gMG Submission in Japan1Q 2023VYVGART ITP Submission in JapanMid-2023

Planned Clinical Milestones

Efgartigimod

•	ADHERE data in CIDP	2Q 2023
•	ADDRESS data in Pemphigus	2H 2023
•	ADVANCE (SC) data in ITP	2H 2023
•	POC data in Post-COVID POTS	4Q 2023
•	Initiate registrational trial in TED	4Q 2023
•	Initiate POC studies in ANCA and	4Q 2023
	AMR	

Additional pipeline


•	ARGX-117: ARDA MMN interim results	Mid-2023
•	ARGX-117: Initiate DGF POC study	2H 2023

1Q 2023

• ARGX-119: Initiate Phase 1 study

* Pending decision from local regulatory authorities

Our mission continues...



Breadth and Depth Within Autoimmune Pipeline

Program	Indication	Preclinical	Phase 1	Proof of Concept	Registrational	Commercial
VYVGART	gMG (IV)					
	gMG (SC)					
	CIDP					
	Myositis					
	Thyroid Eye Disease					
	ITP (IV)					
Efgartigimod	ITP (SC)					1.1.1.1.1.1.1
	COVID-19 Mediated POTS					
	Sjogren's Syndrome					
	Anca Vasculitis					
	Pemphigus					
	Bullous Pemphigoid					
	Membranous Nephropathy					
	Lupus Nephritis					
	Antibody Mediated Rejection			l		
	Multifocal Motor Neuropathy					
ARGX-117	Dermatomyositis					
	Delayed Graft Function After Kidney Transplant					
ARGX-119	Neuromuscular Indications					



argenx

Chronic Inflammatory Demyelinating Polyneuropathy ADHERE Trial

